Due to the absence of AR signaling, these PCa variants become resistant to anti-androgen therapy and constitute an extremely aggressive variant of advanced CRPC, characterized by shorter survival times (<1 year) and limited therapeutic options. The gene discussed is AR; the disease is posterior cortical atrophy.